Date:_Nov.25 th ,2021
Your Name:Lutang Wei
Manuscript Title: The liver X receptor agonist T0901317 reduces the inflammation of alveolar epithelial cells
induced by polyhexamethylene guanidine through inhibition of the NFkB signaling pathway
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interestsas they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity(if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	_ XNone

None

Please place an "X" next to the following statement to indicate your agreement:

Date:_Nov.25 th ,2021
Your Name:Yongzhong Guo
Manuscript Title: The liver X receptor agonist T0901317 reduces the inflammation of alveolar epithelial cells
induced by polyhexamethylene guanidine through inhibition of the NFkB signaling pathway
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interestsas they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
4			
1	All support for the present manuscript (e.g., funding,	_ X None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ X None	
	any entity(if not indicated in		
	item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	XNone

None

Please place an "X" next to the following statement to indicate your agreement:

Date:_Nov.25 th ,2021
Your Name:Xiaoqian Ding
Manuscript Title: The liver X receptor agonist T0901317 reduces the inflammation of alveolar epithelial cells
induced by polyhexamethylene guanidine through inhibition of the NFkB signaling pathway
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interestsas they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
4			
1	All support for the present manuscript (e.g., funding,	_ X None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ X None	
	any entity(if not indicated in		
	item #1 above).		
3	Royalties or licenses	_ X None	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	XNone

None

Please place an "X" next to the following statement to indicate your agreement:

Date:_Nov.25 th ,2021
Your Name:Caihong Guo
Manuscript Title: The liver X receptor agonist T0901317 reduces the inflammation of alveolar epithelial cells
induced by polyhexamethylene guanidine through inhibition of the NFkB signaling pathway
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interestsas they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X None	
	any entity(if not indicated in		
	item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	XNone

None

Please place an "X" next to the following statement to indicate your agreement:

Date:_Nov.25 th ,2021
Your Name:Nan Ge
Manuscript Title: The liver X receptor agonist T0901317 reduces the inflammation of alveolar epithelial cells
induced by polyhexamethylene guanidine through inhibition of the NFkB signaling pathway
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interestsas they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity(if not indicated in item #1 above).	_ XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	XNone

None

Please place an "X" next to the following statement to indicate your agreement:

Date:_Nov.25 th ,2021
Your Name:Dunqiang Ren
Manuscript Title: The liver X receptor agonist T0901317 reduces the inflammation of alveolar epithelial cells
induced by polyhexamethylene guanidine through inhibition of the NFkB signaling pathway
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interestsas they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
4			
1	All support for the present manuscript (e.g., funding,	_ X None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ X None	
	any entity(if not indicated in		
	item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	XNone

None

Please place an "X" next to the following statement to indicate your agreement:

Date:_Nov.25 th ,2021
Your Name:Hongmei Wang
Manuscript Title: The liver X receptor agonist T0901317 reduces the inflammation of alveolar epithelial cells
induced by polyhexamethylene guanidine through inhibition of the NFkB signaling pathway
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interestsas they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
4			
1	All support for the present manuscript (e.g., funding,	_ X None	
	provision of study materials,		
medical	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ X None	
	any entity(if not indicated in		
	item #1 above).		
3	Royalties or licenses	_ X None	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	XNone

None

Please place an "X" next to the following statement to indicate your agreement: